Investment Thesis

.

Competitive Moat

Cencora benefits from significant scale economies and a robust distribution network, which serve as a formidable barrier to entry against smaller competitors. The company's established relationships with healthcare providers and manufacturers create high switching costs, ensuring customer loyalty. Additionally, COR's intangible assets, including proprietary data analytics capabilities and regulatory expertise, enhance its competitive position. While emerging competitors in specialty pharmaceuticals pose a threat, COR's established market presence and operational efficiencies afford it a durable moat over the next 5-10 years.

Growth Engine

Future revenue growth for Cencora will be driven by the increasing demand for specialty pharmaceuticals and a growing focus on home healthcare solutions. The total addressable market (TAM) for pharmaceutical distribution is projected to expand significantly, with estimates suggesting a CAGR of over 5% through 2030. Cencora's strategic initiatives, including geographic expansion and partnerships, will facilitate organic growth, while potential acquisitions could further enhance its market share. Currently, COR is gaining traction in the specialty drug segment, positioning itself as a leader in this lucrative market.